In April 2014 Questcor Pharmaceuticals (NASDAQ:QCOR) was acquired by Mallinckrodt Pharmaceuticals for $5.6 billion in cash and stock. Originally doing business a Ribogene - that went piblic in 1992 - fellow SBIR Awardee Cypros (fba NeuroThera) itself offered another IPO in 1998, acquired the firm in 1999 renaming itQuestcor Pharmaceuticals. Questcor is in the discovery and development of new classes of compounds that act through the translational control of gene expression to treat patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The firmâs efforts are currently focused on the fields of neurology, nephrology and rheumatology; all areas of medicine which have significant unmet medical needs. The firmâs main product is H.P Acthar Gel (repository corticotropin injection), a naturally-derived formulation of adrenocorticotropic hormones that is currently approved in the U.S. for the treatment of acute exacerbations of multiple sclerosis in adults and as a monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, for use during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis), as well as indicated for the treatment of several other diseases and disorder
